Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monkhorst

Showing results (101-110 of 160) with videos related to

Pageof 16
Sort By:
Cancers|January 21, 2022
Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma PatientsLuuk J Schipper, Kim Monkhorst, Kris G Samsom, et al.
Cancers|April 12, 2022
Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical RelevanceSimone N Koole, Daan C L Vessies, Milou M F Schuurbiers, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
Cancer|October 31, 2023
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancerBianca A M H van Veggel, Anthonie J van der Wekken, Marthe S Paats, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2020
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancerSanne C F A Huijberts, Robin M J M van Geel, Emilie M J van Brummelen, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combinationLieke L van der Woude, Mark A J Gorris, Inge M N Wortel, et al.
JTO Clinical and Research Reports|April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLCM Jebbink, A J de Langen, K Monkhorst, et al.
Nature Medicine|April 2, 2026
Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancersJeffrey van Putten, Petur Snaebjornsson, Linda J W Bosch, et al.
Nature Medicine|March 21, 2026
Real-world clinical utility of tumor whole-genome sequencing in solid cancersJeffrey van Putten, Petur Snaebjornsson, Linda J W Bosch, et al.
Journal of Translational Medicine|July 5, 2020
Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinomaW S M E Theelen, O Krijgsman, K Monkhorst, et al.
Pageof 16

Showing results (101-110 of 160) with videos related to

Sort By:
Pageof 16
Cancers|January 21, 2022
Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma PatientsLuuk J Schipper, Kim Monkhorst, Kris G Samsom, et al.
Cancers|April 12, 2022
Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical RelevanceSimone N Koole, Daan C L Vessies, Milou M F Schuurbiers, et al.
JAMA Oncology|July 12, 2019
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical TrialWillemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, et al.
Cancer|October 31, 2023
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancerBianca A M H van Veggel, Anthonie J van der Wekken, Marthe S Paats, et al.
Cancer Chemotherapy and Pharmacology|April 11, 2020
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancerSanne C F A Huijberts, Robin M J M van Geel, Emilie M J van Brummelen, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combinationLieke L van der Woude, Mark A J Gorris, Inge M N Wortel, et al.
JTO Clinical and Research Reports|April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLCM Jebbink, A J de Langen, K Monkhorst, et al.
Nature Medicine|April 2, 2026
Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancersJeffrey van Putten, Petur Snaebjornsson, Linda J W Bosch, et al.
Nature Medicine|March 21, 2026
Real-world clinical utility of tumor whole-genome sequencing in solid cancersJeffrey van Putten, Petur Snaebjornsson, Linda J W Bosch, et al.
Journal of Translational Medicine|July 5, 2020
Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinomaW S M E Theelen, O Krijgsman, K Monkhorst, et al.
Pageof 16